ASCO 2017 – Sunday, June 4

Sunday, June 4

8:00 AM – 11:30 AM
Location: Hall A

POSTER SESSION: Breast Cancer—Local/Regional/Adjuvant
Abstract 521:SWOG S0221 updated: Randomized comparison of chemotherapy schedules in breast cancer adjuvant therapy
Poster Board: #121
G. Thomas Budd, MD – First Author

8:00 AM – 11:30 AM
Location: Hall A

POSTER SESSION: Genitourinary (Nonprostate) Cancer
Abstract 4529: Molecular profiling of small cell bladder cancer (SCBC) to reveal gene expression determinants of an aggressive phenotype
Poster Board: #207
Vadim S. Koshkin, MD – First Author

Abstract 4534: Circulating tumor (ct)-DNA alterations in urothelial/bladder cancer (UC/BC): Updates on a dynamic genomic landscape
Poster Board: #212
Petros Grivas, MD, PhD – First Author

Abstract 4548: Myeloid derived suppressor cells (MDSC) and inflammatory biomarkers in metastatic urothelial carcinoma (mUC)
Poster Board: #226
Moshe Chaim Ornstein, MD, MA – First Author

Abstract 4584: Sunitinib in patients with metastatic renal cell carcinoma: Clinical outcome according to IMDC risk group
Poster Board: #262
Brian I. Rini, MD – First Author

Abstract 4586: Nivolumab treatment for patients with non-clear cell renal cell carcinoma: A multicenter retrospective analysis
Poster Board: #264
Vadim S. Koshkin, MD – First Author

Abstract 4587: T cell infiltration (TCI) in matched renal biopsy (bx) and nephrectomy (nx) samples in renal cell carcinoma (RCC).
Poster Board: #265
Haris Zahoor, MD – First Author

Abstract TPS4597: Phase 3 KEYNOTE-426 trial: Pembrolizumab (pembro) plus axitinib versus sunitinib alone in treatment-naive advanced/metastatic renal cell carcinoma (mRCC)
Poster Board: #271b
Brian I. Rini, MD – First Author

Abstract TPS4600: Tivo-3: A phase 3, randomized, controlled, multi-center, open-label study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced renal cell carcinoma (RCC)
Poster Board: #273a
Brian I. Rini, MD – First Author

8:00 AM – 11:30 AM
Location: Hall A

POSTER SESSION: Sarcoma
Abstract TPS11079: A bi-shRNAfurin and GMCSF engineered autologous tumor cell immunotherapy vs. gemcitabine + docetaxel for Ewing sarcoma and with cryoablation in Ewing family tumors
Poster Board: #402a
Peter Meade Anderson, MD, PhD – First Author

4:45 PM – 6:00 PM
Location: E354b

EDUCATION SESSION: Turning the On-Off Dial: Cancer Epigenetics and Therapy

5:25 PM – 5:45 PM
Higher-Level Pathway Objectives of Epigenetic Therapy: A Solution to the p53 Problem in Cancer?
Yogen Saunthararajah, MD – Speaker